Article Sidebar
Published:
Sep 12, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy and safety of Qishen Yiqi drop pill for coronary heart disease: An overview of systematic review and meta-analysis
Abstract
Purpose: To investigate current pieces of evidence on Qishen Yiqi drop pill (QSYQ) in coronary heart disease (CHD).
Methods: All systematic reviews (SRs) and meta-analyses (Mas) on QSYQ for CHD were collected by searching six databases and evaluated using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2). The grading of recommendations assessment, development, and evaluation (GRADE) system was applied to assess the quality of outcomes.
Results: Five SRs/MAs were analyzed and twenty-four outcome indicators were reported. The AMSTAR 2 revealed that 3 (12.5 %) of the outcome indicators were of moderate quality, 6 (25 %) were of low quality, and 15 (62.5 %) were of deficient quality. Five SRs/MAs (80 %) described adverse reactions, with two reporting no significant adverse reactions and two reporting minor adverse reactions (p > 0.05).
Conclusion: Combining QSYQ with conventional therapy improves CHD patients' electrocardiogram and overall health outcomes. Future high-quality clinical trials and standardized study methods are needed to further investigate the safety of QSYQ.
